Jing Xia

Partner

P 212.216.1158    F 212.216.8001
1350 Broadway
New York, NY 10018

 
P 212.216.1158    F 212.216.8001   jxia@tarterkrinsky.com

Dr. Jing Xia is a partner in the Intellectual Property Practice and is co-chair of the Pharmaceutical and Biologics Practice Group and China Practice Group. She focuses her practice on the representation of major pharmaceutical companies, especially litigations arising under the Drug Price Competition and Patent Term Restoration Act (Hatch Waxman). Dr. Xia represents clients in patent litigation, with a primary focus on Hatch-Waxman Act (ANDA) and Biologics Price Competition and Innovation Act (BPCIA) maters.

A former scientist well versed in pharmacology and biotechnology, she also assists clients in minimizing risks and maximizing returns on prescription small molecule drugs and follow-on biologics (biosimilars) by providing counseling on product selection, formulation design and manufacturing. She has worked on more than three hundred small molecules as well as various biological targets, such as monoclonal antibodies, insulin, oncology products, anti-vascular endothelial growth factor products, anti-interleukin products and anti-tumor necrosis factor products.

She regularly advises clients regarding the procurement, management and licensing of intellectual property assets, and oversees due diligence in mergers and asset purchases. She has prepared contracts involving intellectual property issues such as licenses, consulting, material transfer and sponsored research agreements.

Dr. Xia is fluent in Mandarin Chinese and is regularly invited to speak on U.S. pharmaceutical laws for Chinese pharmaceutical companies and education institutions. With more than a decade of assisting foreign-based companies, she understands issues unique to these companies when opening or growing their business in the United States. Together with the team at Tarter Krinsky & Drogin, she offers value-added service to China-based companies that are establishing U.S. operations, introducing business opportunities and acting as outside general counsel. With her skill set she is able to provide client-centered and cost-effective counsel on legal issues confronting her clients on a daily basis.

Representative Experience

  • Advises a large international generic pharmaceutical company on legal issues relating to ANDA filing and PIV litigation since 2005 and have worked on over 150 ANDA products.
  • Counsels generic companies on ANDA filings, product selection, clearances, opinions and PIV litigations.
  • Serves as an advisor to major international financial institutions on commercial lending and M&A activities.
  • Advises Chinese companies on general corporate issues, immigration, contracts and real estate transactions.
  • Helped to build an ANDA portfolio (worked on over 40 ANDA products) for a small generic company that led to the successful sale of the company to a major pharmaceutical corporation.
  • Provided patent assessments on more than 10 biosimilar products for pharmaceutical companies.
  • Conducted due diligence studies on biotech products (protein products) in an acquisition valued at over 50 million dollars by a major biotech company.

Prior to joining Tarter Krinsky & Drogin, Dr. Xia was as a lawyer at Axinn, Veltrop & Harkrider LLP, Budd Larner PC and Goodwin Procter LLP. She started her career at biotech company, Affymetrix, which is a pioneer in microarray technology and genomic analysis.

Education

Rutgers University, School of Law, J.D. 2011
Columbia University, Ph.D., M.A. and M.Phil., Pharmacology, 2002
Zhejiang University, China, B.S., Biology and Computer Science, 1994

Admissions
  • New Jersey
  • New York
  • U.S. Patent and Trademark Office
  • U.S. District Court, District of New Jersey
  • Tarter Krinsky & Drogin Promotes Four Lawyers

    Tarter Krinsky & Drogin is pleased to announce the promotions of four lawyers, three to partner and one to counsel. The firm's new partners are Brian Beller (Real Estate), Scott Schneider (Real Estate) and Dr. Jing Xia (Intellectual Property). John Rondello (Construction) was promoted to counsel.

  • Jing Xia Joins Tarter Krinsky & Drogin LLP in the Intellectual Property Group

    Tarter Krinsky & Drogin LLP is pleased to welcome Dr. Jing Xia as a Counsel in the Intellectual Property Group. For over ten years, she has concentrated her practice on the representation and counselling of mid to large size generic pharmaceutical clients, especially litigations arising under the Drug Price Competition and Patent Term Restoration Act (Hatch Waxman).

Education

Rutgers University, School of Law, J.D. 2011
Columbia University, Ph.D., M.A. and M.Phil., Pharmacology, 2002
Zhejiang University, China, B.S., Biology and Computer Science, 1994

Admissions
  • New Jersey
  • New York
  • U.S. Patent and Trademark Office
  • U.S. District Court, District of New Jersey